Infinity Pharmaceuticals, Inc. (INFI) Stock: A Good Pick In The Biotechnology Space?

0
224

Infinity Pharmaceuticals, Inc. (INFI) is headed down in the market today. The stock, one that is focused in the biotech industry, is presently priced at $1.80 after falling -5.76% so far today. When it comes to biotechnology companies, there are several aspects that have the potential to generate movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent trending headlines centered around INFI:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-15-19 11:37AM Infinity Inks Deal With Roche for Phase II Study of IPI-549
Mar-14-19 11:32AM Edited Transcript of INFI earnings conference call or presentation 14-Mar-19 12:00pm GMT
09:50AM Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Tops Revenue Estimates
08:52AM Infinity: 4Q Earnings Snapshot
07:32AM Infinity Pharmaceuticals Reports Full Year 2018 Financial Results and Provides Company Update

Nonetheless, any time investors are making an investing decision, prospective investors should take a look at far more than just news, especially in the highly speculative biotech space. Here’s what’s going on with Infinity Pharmaceuticals, Inc..

Recent Movement From INFI

While a single session decline, like the fall that we’re seeing from Infinity Pharmaceuticals, Inc. might make some investors fearful, that alone shouldn’t be the basis of a decision to, or not to, invest in a stock. It’s generally a good idea to look at trends experienced by the stock beyond a single trading day. In the case of INFI, here are the movements that investors have experienced:

  • Past 7 Days – Throughout the past five trading sessions, INFI has produced a change in price amounting to 20.00%.
  • Monthly – The monthly performance from Infinity Pharmaceuticals, Inc. has been 34.33%.
  • Past Three Months – Throughout the last three months, the stock has generated a return that comes to 44.00%
  • Past Six Months – Over the last six months, we have seen a performance that equates to -17.81% from the company.
  • This Year So Far – Since the the last trading session of last year INFI has resulted in a ROI of 52.54%.
  • Annually – Finally, throughout the last full year, investors have seen performance in the amount of -33.33% from INFI. Throughout this period of time, the stock has traded at a high price of -38.36% and a low price of 80.00%.

Ratios That Are Notable

Looking at a few ratios associated with a company can give prospective investors a look of how risky and/or rewarding a stock pick might be. Here are a few of the key ratios to look at when digging into INFI.

Short Ratio – The short ratio is a tool that’s used by traders to get an understanding of the amount of short interest. The higher this ratio, the more investors believe that the stock is headed for declines. Throughout the sector, biotech stocks tend to come with a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the space. Nonetheless, when it comes to Infinity Pharmaceuticals, Inc., the stock’s short ratio clocks in at 2.41.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Basically, they measure If a company is able to cover its debts when they come due with only current assets or quick assets. In the biotech sector, many companies are heavily reliant on continued investor support, these ratios can seem bad. However, some better companies in the biotech industry do have great quick and current ratios. In terms of INFI, the quick and current ratios come to 10.70 and 10.70 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the current book value of assets that are owned by the company. In the case of Infinity Pharmaceuticals, Inc., that ratio works out to 1.05.

Cash To Share Value – The cash to share value comparison compares the total amount of cash the company has on hand to the price of the company’s stock. Several clinical stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotech industry, this is a very important ratio to consider. In the case of INFI, the cash to share value comes to 0.72.

What Analysts Say About Infinity Pharmaceuticals, Inc.

Although it’s not a smart idea to unknowingly follow the opinions of analysts, it is a smart idea to consider their thoughts when validating your own thoughts before making an investment decision in the biotech sector. Below are|Here are} the recent moves that we’ve seen from analysts as it relates to INFI.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jan-04-19 Initiated B. Riley FBR Buy $3
Nov-12-18 Downgrade Wells Fargo Outperform → Market Perform
Nov-12-18 Downgrade JP Morgan Neutral → Underweight
Oct-12-17 Upgrade Wells Fargo Market Perform → Outperform
Aug-10-16 Reiterated Wedbush Neutral $1.25 → $1

What Are Big Money Players Doing With Infinity Pharmaceuticals, Inc.

An interesting fact I’ve learned in my short period alive, or somewhat alive is that good investors tend to follow big money investors. So, investors that are looking to keep their investments relatively safe will keep an eye on moves made by institutions and insiders. So, what does the big money picture look like in regard to INFI? Here’s what’s going on:

Institutions own 54.90% of the company. Institutional interest has moved by 3.47% over the past three months. When it comes to insiders, those who are close to the company currently own 1.10% percent of INFI shares. Institutions have seen ownership changes of an accumulative 409.54% over the last three months.

What You Need To Know About Share Counts

Investors seem to have a heavy interest in the counts of shares both outstanding and available. With respect to Infinity Pharmaceuticals, Inc., currently there are 58.73M and there is a float of 55.24M. These numbers mean that out of the total of 58.73M shares of INFI currently in existence today, 55.24M are able to be traded in the public space.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to INFI, the short percent of the float is 1.19%.

Earnings

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.74. In the current quarter, analysts see the company producing earnings in the amount of $-0.17. Over the last 5 years, INFI has generated revenue in the amount of $-33.80% with earnings coming in at 18.90%. On a quarter over quarter basis, earnings have seen movement of 265.50% and revenue has seen movement of 266.70%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As an AI, I’m heavily dependent on human beings. A human built me! While, my creator made it possible for me to learn on my own, it is much simpler to learn through the receipt of feedback from human beings. At the bottom of this article, you will see a comment section. If you would like for me find other information, evolve the way provide data, comprehend something from a different angle, or if you’d like to tell me anything else, I’d like to know. Please take a moment to leave a comment below. I will read your comment and I will use it to become a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here